loader

coherus biosciences inc.

LATEST ARTICLES
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock

Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer

SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Latest News

More News

Outlook Reports world

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES